Stock Research: T Man Pharmaceutical

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

T Man Pharmaceutical

SET:TMAN THC209010006
75
  • Value
    67
  • Growth
    75
  • Safety
    Safety
    54
  • Combined
    78
  • Sentiment
    49
  • 360° View
    360° View
    75
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

ANALYSIS: With an Obermatt 360° View of 75 (better than 75% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock T Man Pharmaceutical are very positive. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators above average for T Man Pharmaceutical. The consolidated Value Rank has an attractive rank of 67, which means that the share price of T Man Pharmaceutical is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 67% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 75, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. The company is also safely financed with a Safety Rank of 54. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of only 49. Professional investors are more confident in 51% other stocks. ...read more

more
Index
SET
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 26-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
67 n/a n/a n/a
Growth
75 n/a n/a n/a
Safety
Safety
54 n/a n/a n/a
Sentiment
49 n/a n/a n/a
360° View
360° View
75 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
100 n/a n/a n/a
Opinions Change
50 n/a n/a n/a
Pro Holdings
n/a n/a n/a n/a
Market Pulse
43 n/a n/a n/a
Sentiment
49 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
67 n/a n/a n/a
Growth
75 n/a n/a n/a
Safety Safety
54 n/a n/a n/a
Combined
78 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
48 n/a n/a n/a
Price vs. Earnings (P/E)
64 n/a n/a n/a
Price vs. Book (P/B)
32 n/a n/a n/a
Dividend Yield
81 n/a n/a n/a
Value
67 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
72 n/a n/a n/a
Profit Growth
25 n/a n/a n/a
Capital Growth
90 n/a n/a n/a
Stock Returns
61 n/a n/a n/a
Growth
75 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
43 n/a n/a n/a
Refinancing
67 n/a n/a n/a
Liquidity
64 n/a n/a n/a
Safety Safety
54 n/a n/a n/a

Similar Stocks

Discover high‑ranked alternatives to T Man Pharmaceutical and broaden your portfolio horizons.

AP Thailand

SET:AP
Country: Thailand
Industry: Real Estate Development
Size: Large
Full Stock Analysis

Sri Trang Gloves (Thailand)

SET:STGT
Country: Thailand
Industry: Health Care Supplies
Size: Medium
Full Stock Analysis

Asian Sea Corporation

SET:ASIAN
Country: Thailand
Industry: Packaged Foods & Meats
Size: Medium
Full Stock Analysis

Kalbe Farma

JKT:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Frequently Asked
Questions

This stock has excellent financial qualities (value, growth, and safety are high) but a negative professional market sentiment. It suits an investor who believes the negative sentiment is a temporary overreaction and is looking for a financially solid company.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: